Recent coverage of innovative research and development across the biopharma and medtech sectors.
READ NOWFeatured Stories
Market Access Strategies: Nudging Negotiations Along
Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?
Market Prices Or Political Expediency? Amgen’s US Lawsuit Seen As Litmus Test
As the US struggles to contain the cost of prescription medicines, a growing number of state governments are trying to take matters into their own hands and believe prescription drug affordability boards could be the answer.
Overcoming The Challenges Of Developing Hearing Loss Therapies
Hearing loss remains an area in dire need of new treatments, and while new approaches such as regenerative and gene therapies are under development, running clinical trials involves a number of challenges, according to speakers at a UK webinar.
Latest Articles
Balancing Up The Clinician Burnout-AI Equation
The medical industry must scale up to meet rising demand for care with fewer clinicians. Artificial intelligence can take care to the next levels of volume and quality – and in equity of delivery, insists the company, Annalise.ai.
Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority
Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.
H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
Biotech’s Next Goal: ‘Addressing Resistance’ In The ADC Space
George Badescu, chief business officer at Heidelberg Pharma, discusses antibody-drug conjugate development, partnership styles and the appetite for risk-taking in the biopharma industry.
Overcoming The Challenges Of Developing Hearing Loss Therapies
Hearing loss remains an area in dire need of new treatments, and while new approaches such as regenerative and gene therapies are under development, running clinical trials involves a number of challenges, according to speakers at a UK webinar.
'Not Going With The Crowd’: Mapping Gene Potential With ProFound Therapeutics
John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.
Could AI Help Vaccine Developers See Into The Future?
Rapidly-mutating viruses can easily outpace even the fastest vaccine developers. To prevent another pandemic, biotechs are hoping AI might be able to predict mutations of concern and design vaccines against them before they arise.
Why Is Animal Testing Still With Us?
Despite increased openness by regulators and technological progress, the adoption of alternatives to animal testing remains challenging. The need for data validation by agencies and companies is a big factor.
'Not Going With The Crowd’: Mapping Gene Potential With ProFound Therapeutics
John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.
Schumacher Looks To Steer Tubulis To The Top Of The ADC Tree
It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.
Execs On The Move: July 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Boehringer R&D Exec: ‘People Are Longing For Connection’
In her role as Boehringer's senior vice president and global head of Development Sciences, Xiaorong He emphasizes patient-centric innovation and sustainability. She is committed to incorporating patient insights into product development and advancing eco-friendly practices within the company's R&D pipeline.
Market Prices Or Political Expediency? Amgen’s US Lawsuit Seen As Litmus Test
As the US struggles to contain the cost of prescription medicines, a growing number of state governments are trying to take matters into their own hands and believe prescription drug affordability boards could be the answer.
The Future Of Medical Evidence Generation
Boston Consulting Group and senior pharma industry executives take a broad look at the challenges and opportunities for medical affairs evidence generation with multiple modalities.
Market Access Strategies: Nudging Negotiations Along
Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?
Why EU App Makers May Need A Notified Body More Often Than They Realized
Any apps, or indeed any software, which assist communication in the medical field need to be carefully evaluated against a tricky-to-comprehend rule in the EU’s Medical Device Regulation.
2025’s Therapy Area Growth Drivers And Brakes: Part Two
The second instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on blood malignancies, skin conditions and generalized cardiovascular disease.
US Adalimumab Outlook Brightens At Mid-Point Of 2024
The latest figures on uptake of rivals to AbbVie's Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator after an initially slow start in 2023.
Deal Volume Up, Value Down During The First Half
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.
2023-2024 Global Biopharma R&D Productivity And Growth Ranking
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
The Future Of Medical Evidence Generation
Boston Consulting Group and senior pharma industry executives take a broad look at the challenges and opportunities for medical affairs evidence generation with multiple modalities.
'Not Going With The Crowd’: Mapping Gene Potential With ProFound Therapeutics
John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.
Shape Our Content: Take The Reader Survey
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
Could AI Help Vaccine Developers See Into The Future?
Rapidly-mutating viruses can easily outpace even the fastest vaccine developers. To prevent another pandemic, biotechs are hoping AI might be able to predict mutations of concern and design vaccines against them before they arise.
Why Is Animal Testing Still With Us?
Despite increased openness by regulators and technological progress, the adoption of alternatives to animal testing remains challenging. The need for data validation by agencies and companies is a big factor.
Balancing Up The Clinician Burnout-AI Equation
The medical industry must scale up to meet rising demand for care with fewer clinicians. Artificial intelligence can take care to the next levels of volume and quality – and in equity of delivery, insists the company, Annalise.ai.
Market Access Strategies: Nudging Negotiations Along
Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?
2025’s Therapy Area Growth Drivers And Brakes: Part Two
The second instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on blood malignancies, skin conditions and generalized cardiovascular disease.
Why EU App Makers May Need A Notified Body More Often Than They Realized
Any apps, or indeed any software, which assist communication in the medical field need to be carefully evaluated against a tricky-to-comprehend rule in the EU’s Medical Device Regulation.
US Adalimumab Outlook Brightens At Mid-Point Of 2024
The latest figures on uptake of rivals to AbbVie's Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator after an initially slow start in 2023.
Mpox: WHO Steps Up Calls For Urgent Prevention And Vaccination Efforts
National authorities urged to address knowledge gaps and generate evidence about the dynamics of mpox transmission.
Deal Volume Up, Value Down During The First Half
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.